|
Dr. William Hunter is one of Angiotech’s co-founders and currently serves as President and CEO of the company. He has led Angiotech through significant corporate milestones from its initial rounds of private and public financings, to product commercialization and profitability. The company’s initial lead product, the TAXUS® drug-eluting coronary stent which was co-developed and is now sold by Boston Scientific Corporation is implanted in over three million patients worldwide. Today, Angiotech is a global leader in the field of drug-device combination products and a major manufacturer of over 5,000 specialty, single-use medical devices and medical device components targeting various surgical and interventional medical markets. Active in a variety of business and scientific organizations, Dr. Hunter serves as the chair of the board for Neuromed Pharmaceuticals Ltd. and is also a director on the boards of Aspreva Pharmaceuticals Corporation and The Michael Smith Foundation for Health Research. He is an advisory board member for the Biotechnology MBA Program at the University of Western Ontario’s Ivey School of Business and a member of the Government of British Columbia Premier’s Technology Council.
| 